Related references
Note: Only part of the references are listed.Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
Gamal Shiha et al.
GUT (2019)
Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
G. Shiha et al.
HEPATOLOGY INTERNATIONAL (2018)
A novel single daily fixed dose combination of sofosbuvir 400 mg+ribavirin1000 mg + EGCG 400 mg is superior to the standard of care as an anti-viral and safer causing less hemolysis in patients with chronic hepatitis C
G. Shiha et al.
JOURNAL OF HEPATOLOGY (2017)
Hepatitis C virus management: potential impact of nanotechnology
Mostafa H. Elberry et al.
VIROLOGY JOURNAL (2017)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial
Imam Waked et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry
Peter J. Ruane et al.
JOURNAL OF HEPATOLOGY (2015)
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4
Wahid Doss et al.
JOURNAL OF HEPATOLOGY (2015)
Interferon-free, direct-acting antiviral therapy for chronic hepatitis C
J. A. Gutierrez et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
Noemie Calland et al.
JOURNAL OF VIROLOGY (2015)
Sofosbuvir as backbone of interferon free treatments
Marc Bourliere et al.
DIGESTIVE AND LIVER DISEASE (2014)
Will There Be a Vaccine to Prevent HCV Infection?
Jonathan R. Honegger et al.
SEMINARS IN LIVER DISEASE (2014)
Epigallocatechin gallate, the major component of polyphenols in green tea, inhibits telomere attrition mediated cardiomyocyte apoptosis in cardiac hypertrophy
Rui Sheng et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Green Tea Phenolic Epicatechins Inhibit Hepatitis C Virus Replication via Cycloxygenase-2 and Attenuate Virus-Induced Inflammation
Ying-Ting Lin et al.
PLOS ONE (2013)
Apolipoprotein E Mediates Attachment of Clinical Hepatitis C Virus to Hepatocytes by Binding to Cell Surface Heparan Sulfate Proteoglycan Receptors
Jieyun Jiang et al.
PLOS ONE (2013)
(-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus
Chao Chen et al.
ARCHIVES OF VIROLOGY (2012)
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
Christoph Welsch et al.
GUT (2012)
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
Noemie Calland et al.
HEPATOLOGY (2012)
Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps
Viet Loan Dao Thi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naive Infected Individuals
Salvador Fonseca-Coronado et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
Ann D. Kwong et al.
NATURE BIOTECHNOLOGY (2011)
Effects of epigallocatechin gallate on the hemolysis induced by cyclosporine
HC Kim et al.
TRANSPLANTATION PROCEEDINGS (2005)
Tea catechins with a galloyl moiety suppress postprandial hypertriacylglycerolemia by delaying lymphatic transport of dietary fat in rats
I Ikeda et al.
JOURNAL OF NUTRITION (2005)
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate
H Barth et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Share Paper
